444 related articles for article (PubMed ID: 33053331)
1. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8
Weulersse M; Asrir A; Pichler AC; Lemaitre L; Braun M; Carrié N; Joubert MV; Le Moine M; Do Souto L; Gaud G; Das I; Brauns E; Scarlata CM; Morandi E; Sundarrajan A; Cuisinier M; Buisson L; Maheo S; Kassem S; Agesta A; Pérès M; Verhoeyen E; Martinez A; Mazieres J; Dupré L; Gossye T; Pancaldi V; Guillerey C; Ayyoub M; Dejean AS; Saoudi A; Goriely S; Avet-Loiseau H; Bald T; Smyth MJ; Martinet L
Immunity; 2020 Oct; 53(4):824-839.e10. PubMed ID: 33053331
[TBL] [Abstract][Full Text] [Related]
2. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8
Braun M; Aguilera AR; Sundarrajan A; Corvino D; Stannard K; Krumeich S; Das I; Lima LG; Meza Guzman LG; Li K; Li R; Salim N; Jorge MV; Ham S; Kelly G; Vari F; Lepletier A; Raghavendra A; Pearson S; Madore J; Jacquelin S; Effern M; Quine B; Koufariotis LT; Casey M; Nakamura K; Seo EY; Hölzel M; Geyer M; Kristiansen G; Taheri T; Ahern E; Hughes BGM; Wilmott JS; Long GV; Scolyer RA; Batstone MD; Landsberg J; Dietrich D; Pop OT; Flatz L; Dougall WC; Veillette A; Nicholson SE; Möller A; Johnston RJ; Martinet L; Smyth MJ; Bald T
Immunity; 2020 Oct; 53(4):805-823.e15. PubMed ID: 33053330
[TBL] [Abstract][Full Text] [Related]
3. CD226
Jin HS; Ko M; Choi DS; Kim JH; Lee DH; Kang SH; Kim I; Lee HJ; Choi EK; Kim KP; Yoo C; Park Y
Cancer Immunol Res; 2020 Jul; 8(7):912-925. PubMed ID: 32265229
[TBL] [Abstract][Full Text] [Related]
4.
Wang B; Zhang W; Jankovic V; Golubov J; Poon P; Oswald EM; Gurer C; Wei J; Ramos I; Wu Q; Waite J; Ni M; Adler C; Wei Y; Macdonald L; Rowlands T; Brydges S; Siao J; Poueymirou W; MacDonald D; Yancopoulos GD; Sleeman MA; Murphy AJ; Skokos D
Sci Immunol; 2018 Nov; 3(29):. PubMed ID: 30389797
[TBL] [Abstract][Full Text] [Related]
5. CD8
Wang M; Bu J; Zhou M; Sido J; Lin Y; Liu G; Lin Q; Xu X; Leavenworth JW; Shen E
Clin Immunol; 2018 May; 190():64-73. PubMed ID: 28893624
[TBL] [Abstract][Full Text] [Related]
6. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
7. Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer.
Ma P; Sun W
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14597-14617. PubMed ID: 37580402
[TBL] [Abstract][Full Text] [Related]
8. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
[TBL] [Abstract][Full Text] [Related]
9. An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.
Mittal P; Abblett R; Ryan JM; Hagymasi AT; Agyekum-Yamoah A; Svedova J; Reiner SL; St Rose MC; Hanley MP; Vella AT; Adler AJ
J Immunol; 2018 Feb; 200(4):1513-1526. PubMed ID: 29305435
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8
Banta KL; Xu X; Chitre AS; Au-Yeung A; Takahashi C; O'Gorman WE; Wu TD; Mittman S; Cubas R; Comps-Agrar L; Fulzele A; Bennett EJ; Grogan JL; Hui E; Chiang EY; Mellman I
Immunity; 2022 Mar; 55(3):512-526.e9. PubMed ID: 35263569
[TBL] [Abstract][Full Text] [Related]
11. BCL9 regulates CD226 and CD96 checkpoints in CD8
Feng M; Wu Z; Zhou Y; Wei Z; Tian E; Mei S; Zhu Y; Liu C; He F; Li H; Xie C; Jin J; Dong J; Yang D; Yu K; Qian J; Lambrechts D; Wang MW; Zhu D
Signal Transduct Target Ther; 2021 Aug; 6(1):313. PubMed ID: 34417435
[TBL] [Abstract][Full Text] [Related]
12. Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
Guillerey C; Ferrari de Andrade L; Vuckovic S; Miles K; Ngiow SF; Yong MC; Teng MW; Colonna M; Ritchie DS; Chesi M; Bergsagel PL; Hill GR; Smyth MJ; Martinet L
J Clin Invest; 2015 May; 125(5):2077-89. PubMed ID: 25893601
[TBL] [Abstract][Full Text] [Related]
13. TCR-independent CD137 (4-1BB) signaling promotes CD8
Pichler AC; Carrié N; Cuisinier M; Ghazali S; Voisin A; Axisa PP; Tosolini M; Mazzotti C; Golec DP; Maheo S; do Souto L; Ekren R; Blanquart E; Lemaitre L; Feliu V; Joubert MV; Cannons JL; Guillerey C; Avet-Loiseau H; Watts TH; Salomon BL; Joffre O; Grinberg-Bleyer Y; Schwartzberg PL; Lucca LE; Martinet L
Immunity; 2023 Jul; 56(7):1631-1648.e10. PubMed ID: 37392737
[TBL] [Abstract][Full Text] [Related]
14. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8
Li J; Lee Y; Li Y; Jiang Y; Lu H; Zang W; Zhao X; Liu L; Chen Y; Tan H; Yang Z; Zhang MQ; Mak TW; Ni L; Dong C
Immunity; 2018 Apr; 48(4):773-786.e5. PubMed ID: 29625896
[TBL] [Abstract][Full Text] [Related]
15. NFκB-Pim-1-Eomesodermin axis is critical for maintaining CD8 T-cell memory quality.
Knudson KM; Pritzl CJ; Saxena V; Altman A; Daniels MA; Teixeiro E
Proc Natl Acad Sci U S A; 2017 Feb; 114(9):E1659-E1667. PubMed ID: 28193872
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
17. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
Gros A; Robbins PF; Yao X; Li YF; Turcotte S; Tran E; Wunderlich JR; Mixon A; Farid S; Dudley ME; Hanada K; Almeida JR; Darko S; Douek DC; Yang JC; Rosenberg SA
J Clin Invest; 2014 May; 124(5):2246-59. PubMed ID: 24667641
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
19. Targeting novel inhibitory receptors in cancer immunotherapy.
Ding QQ; Chauvin JM; Zarour HM
Semin Immunol; 2020 Jun; 49():101436. PubMed ID: 33288379
[TBL] [Abstract][Full Text] [Related]
20. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
